Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

Summary

The purpose of this study is to evaluate the safety and anti-tumor effect of rociletinib when administered in combination with trametinib.

Timeline

Start

2015-09-30

Primary completion

2016-05-05

Completion

2016-06-27

Outcome

Outcome not reported

Stopped (Enrollment): “Discontinued development of rociletinib in NSCLC. Stopped enrollment of new patients into all studies involving rociletinib.”

Drugs

Indications